YIDU TECH (02158) reevaluates the AI medical value behind the HK$150 million share repurchase and 3.5% treasury stock within the year.

On March 4th, YIDU TECH (02158) once again refreshed the market's awareness with intensive buybacks. The company repurchased nearly 6.5 million shares at around HK$5.51 per share, spending over HK$35 million, setting a new record for the highest daily repurchase amount. The day before, the company spent HK$22.7616 million, ranking in the top three of the Hong Kong stock buyback list, just behind XIAOMI-W and GEELY AUTO. In just three trading days, the company's cumulative repurchase amount exceeded HK$75 million. Since the start of this year's buyback on January 26th, YIDU TECH has carried out 22 repurchases, with a total investment of over HK$150 million, and a total repurchased shares of 26.72 million shares for the year. As of now, the company's total treasury shares have reached 36.9359 million shares, accounting for 3.5% of the total share capital. Against the backdrop of the overall contraction in Hong Kong's buyback scale, YIDU TECH's intensive operations stand out. It is believed that this sustained capital operation is not simply a financial operation, but a deep dialogue between management and the market. Of particular interest is the high level of treasury shares at 3.5%. In the historical context of the Hong Kong stock market, this ratio is not common. Generally speaking, a repurchase ratio of 1% for a listed company is considered a positive signal, while exceeding 3% often means that the company is undergoing substantial capital structure optimization or is building up "ammunition" for future equity incentives. Looking ahead, the high proportion of treasury shares held by YIDU TECH implies that the company may be brewing larger strategic actions - whether through reducing share capital to improve earnings per share (EPS), establishing long-term incentive mechanisms for core talent teams, or making significant breakthroughs in performance. The policy environment is also strong. During the National Two Sessions, "AI + Medical" became a hot topic of discussion, and YIDU TECH has long been deeply involved in this area. The company's infectious disease monitoring and early warning project supported by core technology in the Hainan Free Trade Port was selected as a national-level case, while its "Yidu Intelligent Circulation" clinical evidence-based intelligent system has entered the internal testing phase - these developments confirm the high degree of alignment between its business layout and national strategy. In the era of "artificial intelligence + empowering all industries", YIDU TECH's current buyback has surpassed a simple financial operation. It is a precise discovery of value, a firm vote for the long-term prospects of the AI medical field, and a key footnote for the company's transition from technological leadership to ecological leadership. With the flexible use of the treasury stock mechanism and the continuous improvement of the business ecosystem, the journey of reevaluating the value of this AI medical pioneer has just begun.